Market Research Report
Endothelial Dysfunction - Pipeline Review, H2 2014
|Published by||Global Markets Direct||Product code||302500|
|Published||Content info||32 Pages
|Endothelial Dysfunction - Pipeline Review, H2 2014|
|Published: November 14, 2014||Content info: 32 Pages||
This publication has been discontinued on January 18, 2018.
Global Markets Direct's, 'Endothelial Dysfunction - Pipeline Review, H2 2014', provides an overview of the Endothelial Dysfunction's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Endothelial Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endothelial Dysfunction and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.